| Name | Title | Contact Details |
|---|
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
Cofactor Genomics is pioneering the use of RNA to diagnose disease.
United States Biological Corporation is a Marblehead, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.